Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$16.48 USD
+1.56 (10.46%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $16.49 +0.01 (0.06%) 7:40 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Day One Biopharmaceuticals, Inc. [DAWN]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
At the DAWN of Tovos PDUFA, a Look at Programs on the Horizon Furthers Our Overall Conviction
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for DAWN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financial Results; Updated FIREFLY-1 Data at SNO
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A New DAWN Approaches For Tovo as FDA Sets PDUFA for April 24
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Receives Priority Review; PDUFA of April 30, 2024
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updated FIREFLY-1 Data; Rolling NDA Submission to FDA Completed
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Continues Its Positive Momentum Toward Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Continues On the Road Toward Approval in r/pLGG; Reit Buy and $50PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; On Track for Tovorafenib NDA Filing in October 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R